Structure-Based Prediction of Asparagine and Aspartate Degradation Sites in Antibody Variable Regions

Monoclonal antibodies (mAbs) and proteins containing antibody domains are the most prevalent class of biotherapeutics in diverse indication areas. Today, established techniques such as immunization or phage display allow for an efficient generation of new mAbs. Besides functional properties, the stability of future therapeutic mAbs is a key selection criterion which is essential for the development of a drug candidate into a marketed product. Therapeutic proteins may degrade via asparagine (Asn) deamidation and aspartate (Asp) isomerization, but the factors responsible for such degradation remain poorly understood. We studied the structural properties of a large, uniform dataset of Asn and Asp residues in the variable domains of antibodies. Their structural parameters were correlated with the degradation propensities measured by mass spectrometry. We show that degradation hotspots can be characterized by their conformational flexibility, the size of the C-terminally flanking amino acid residue, and secondary structural parameters. From these results we derive an accurate in silico prediction method for the degradation propensity of both Asn and Asp residues in the complementarity-determining regions (CDRs) of mAbs.

[1]  Benjamin E. Deverman,et al.  Chronoregulation by Asparagine Deamidation , 2007, Science's STKE.

[2]  V. Katta,et al.  Identification of isomerization and racemization of aspartate in the Asp-Asp motifs of a therapeutic protein. , 2011, Analytical biochemistry.

[3]  Nia Beckley,et al.  Isomerization of Asp-Asp motif in model peptides and a monoclonal antibody Fab fragment. , 2013, Journal of pharmaceutical sciences.

[4]  Lisa Yan,et al.  LOOPER: a molecular mechanics-based algorithm for protein loop prediction. , 2008, Protein engineering, design & selection : PEDS.

[5]  Daniel J. Kroon,et al.  Identification of Sites of Degradation in a Therapeutic Monoclonal Antibody by Peptide Mapping , 1992, Pharmaceutical Research.

[6]  T. Ueda,et al.  Isolation and characterization of 101-succinimide lysozyme that possesses the cyclic imide at Asp101-Gly102. , 1994, Biochemistry.

[7]  Z. Shahrokh,et al.  Peptide mapping with liquid chromatography using a basic mobile phase. , 2008, Journal of chromatography. A.

[8]  B. Kabakoff,et al.  Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[9]  T. Furuchi,et al.  Suppression of protein l-isoaspartyl (d-aspartyl) methyltransferase results in hyperactivation of EGF-stimulated MEK-ERK signaling in cultured mammalian cells. , 2008, Biochemical and biophysical research communications.

[10]  Yi-Zeng Liang,et al.  Monte Carlo cross validation , 2001 .

[11]  R. Borchardt,et al.  Reactivity toward deamidation of asparagine residues in beta-turn structures. , 2000, The journal of peptide research : official journal of the American Peptide Society.

[12]  John F. Valliere-Douglass,et al.  Separation and characterization of an IgG2 antibody containing a cyclic imide in CDR1 of light chain by hydrophobic interaction chromatography and mass spectrometry. , 2008, Analytical chemistry.

[13]  K. Lampi,et al.  Deamidation destabilizes and triggers aggregation of a lens protein, βA3‐crystallin , 2008, Protein science : a publication of the Protein Society.

[14]  J. Kindrachuk,et al.  The Influence of Protein Structure on the Products Emerging from Succinimide Hydrolysis* , 2002, The Journal of Biological Chemistry.

[15]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[16]  Wei Zhang,et al.  Analysis of isoaspartate in a recombinant monoclonal antibody and its charge isoforms. , 2003, Journal of pharmaceutical and biomedical analysis.

[17]  T. Hoffmann,et al.  Isoaspartate residues dramatically influence substrate recognition and turnover by proteases , 2008, Biological chemistry.

[18]  Vasumathi Dharmavaram,et al.  Multivariate Analysis of the Sequence Dependence of Asparagine Deamidation Rates in Peptides , 2009, Pharmaceutical Research.

[19]  R. Ionescu,et al.  Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. , 2008, Current pharmaceutical biotechnology.

[20]  A. Rees,et al.  Antibody variable regions: toward a unified modeling method. , 2004, Methods in molecular biology.

[21]  Yaning Wang,et al.  Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis. , 2011, Analytical chemistry.

[22]  R. Borchardt,et al.  Chemical Pathways of Peptide Degradation. VI. Effect of the Primary Sequence on the Pathways of Degradation of Aspartyl Residues in Model Hexapeptides , 1994, Pharmaceutical Research.

[23]  S Capasso Estimation of the deamidation rate of asparagine side chains. , 2000, The journal of peptide research : official journal of the American Peptide Society.

[24]  A. Kossiakoff,et al.  Tertiary structure is a principal determinant to protein deamidation. , 1988, Science.

[25]  R. Borchardt,et al.  Chemical Pathways of Peptide Degradation. IV. Pathways, Kinetics, and Mechanism of Degradation of an Aspartyl Residue in a Model Hexapeptide , 2004, Pharmaceutical Research.

[26]  E. Topp,et al.  Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody , 2009, Protein science : a publication of the Protein Society.

[27]  R. Bischoff,et al.  Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology. , 1994, Journal of chromatography. B, Biomedical applications.

[28]  D. Chelius,et al.  18O labeling method for identification and quantification of succinimide in proteins. , 2007, Analytical chemistry.

[29]  H. Scheraga,et al.  Stepwise deamidation of ribonuclease A at five sites determined by top down mass spectrometry. , 2006, Biochemistry.

[30]  Alain Van Dorsselaer,et al.  Characterization of therapeutic antibodies and related products. , 2013, Analytical chemistry.

[31]  J. M. Beals,et al.  In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. , 2005, Analytical chemistry.

[32]  Alain Beck,et al.  Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. , 2009, Analytical biochemistry.

[33]  S. Clarke,et al.  Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: Effects of the solvent dielectric , 1993, Protein science : a publication of the Protein Society.

[34]  Jack Y. Zheng,et al.  Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. , 2006, International journal of pharmaceutics.

[35]  R Tyler-Cross,et al.  Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. , 1991, The Journal of biological chemistry.

[36]  S. Weintraub,et al.  Asparagine deamidation: a regulatory hourglass , 2004, Mechanisms of Ageing and Development.

[37]  Characterization of the Isomerization Products of Aspartate Residues at Two Different Sites in a Monoclonal Antibody , 2011, Pharmaceutical Research.

[38]  A. Lesk,et al.  Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.

[39]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[40]  A. Rees,et al.  Antibody Variable Regions , 2004 .

[41]  Bernhardt L. Trout,et al.  Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.

[42]  Ellen M. Langer,et al.  Bcl-xL Deamidation Is a Critical Switch in the Regulation of the Response to DNA Damage , 2002, Cell.

[43]  D. Chelius,et al.  Accumulation of Succinimide in a Recombinant Monoclonal Antibody in Mildly Acidic Buffers Under Elevated Temperatures , 2007, Pharmaceutical Research.

[44]  Viktorya Aviyente,et al.  Deamidation of asparagine residues: direct hydrolysis versus succinimide-mediated deamidation mechanisms. , 2009, The journal of physical chemistry. A.

[45]  S. Clarke,et al.  Effect of adjacent histidine and cysteine residues on the spontaneous degradation of asparaginyl- and aspartyl-containing peptides. , 2009, International journal of peptide and protein research.

[46]  B. Yan,et al.  Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. , 2009, Journal of pharmaceutical sciences.

[47]  Richard J Simpson,et al.  Stabilization of proteins for storage. , 2010, Cold Spring Harbor protocols.

[48]  H. Wright Sequence and structure determinants of the nonenzymatic deamidation of asparagine and glutamine residues in proteins. , 1991, Protein engineering.

[49]  R. Zhao,et al.  An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation. , 2004, Cancer cell.

[50]  M. Matsumura,et al.  Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. , 2008, Biochemistry.

[51]  A. Green,et al.  DNA Damage–Induced Bcl-xL Deamidation Is Mediated by NHE-1 Antiport Regulated Intracellular pH , 2006, PLoS biology.

[52]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[53]  Gang Xiao,et al.  Identification and quantification of degradations in the Asp-Asp motifs of a recombinant monoclonal antibody. , 2008, Journal of pharmaceutical and biomedical analysis.

[54]  J. Shao Linear Model Selection by Cross-validation , 1993 .

[55]  S. Clarke,et al.  Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. , 1989, The Journal of biological chemistry.

[56]  M. Mølhøj,et al.  Simultaneous Assessment of Asp Isomerization and Asn Deamidation in Recombinant Antibodies by LC-MS following Incubation at Elevated Temperatures , 2012, PloS one.

[57]  Patrick G. Swann,et al.  Considerations for the development of therapeutic monoclonal antibodies. , 2008, Current opinion in immunology.

[58]  N. Robinson,et al.  Prediction of protein deamidation rates from primary and three-dimensional structure , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. D. Nielsen,et al.  Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass. , 2014, Journal of pharmaceutical sciences.

[60]  Margit Jeschke,et al.  Determination of the Origin of Charge Heterogeneity in a Murine Monoclonal Antibody , 2000, Pharmaceutical Research.

[61]  A Tramontano,et al.  Conformations of the third hypervariable region in the VH domain of immunoglobulins. , 1998, Journal of molecular biology.

[62]  Kurt Hornik,et al.  kernlab - An S4 Package for Kernel Methods in R , 2004 .

[63]  N. Robinson,et al.  Protein deamidation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  D. Urry,et al.  Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins. , 1991, Critical reviews in biochemistry and molecular biology.

[65]  R. Schowen,et al.  Secondary structure and protein deamidation. , 1999, Journal of pharmaceutical sciences.

[66]  S. Clarke Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. , 2009, International journal of peptide and protein research.

[67]  D. Hambly,et al.  Detection and quantitation of IgG 1 hinge aspartate isomerization: a rapid degradation in stressed stability studies. , 2009, Analytical chemistry.

[68]  Tilman Schlothauer,et al.  Assessment of chemical modifications of sites in the CDRs of recombinant antibodies , 2014, mAbs.

[69]  T. Hoffmann,et al.  Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential β-secretases , 2008, Biological chemistry.

[70]  Kurt Hornik,et al.  Misc Functions of the Department of Statistics (e1071), TU Wien , 2014 .

[71]  William N. Venables,et al.  Modern Applied Statistics with S , 2010 .

[72]  A. Lesk,et al.  Conformations of immunoglobulin hypervariable regions , 1989, Nature.

[73]  Andrew J. Martin,et al.  Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. , 1996, Journal of molecular biology.

[74]  Aditya A Wakankar,et al.  The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. , 2007, Journal of pharmaceutical sciences.

[75]  N. Robinson,et al.  Molecular clocks. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Claus Weihs,et al.  klaR Analyzing German Business Cycles , 2005, Data Analysis and Decision Support.

[77]  N. Robinson,et al.  Deamidation of human proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  K. Lampi,et al.  Deamidation alters the structure and decreases the stability of human lens betaA3-crystallin. , 2007, Biochemistry.

[79]  Ronald T Borchardt,et al.  Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. , 2006, Journal of pharmaceutical sciences.

[80]  Hongcheng Liu,et al.  Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[81]  Douglas S Rehder,et al.  Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. , 2005, Analytical chemistry.

[82]  R. Zubarev,et al.  Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides , 2010, Electrophoresis.

[83]  R. Borchardt,et al.  Chemical Pathways of Peptide Degradation. VII. Solid State Chemical Instability of an Aspartyl Residue in a Model Hexapeptide , 1994, Pharmaceutical Research.

[84]  Russell Huby,et al.  Non-enzymic post-translational modification of proteins in aging. A review , 1989, Mechanisms of Ageing and Development.

[85]  R. Borchardt,et al.  Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.

[86]  D. Brems,et al.  The effects of alpha‐helix on the stability of Asn residues: Deamidation rates in peptides of varying helicity , 2008, Protein science : a publication of the Protein Society.

[87]  A. B. Robinson,et al.  Controlled deamidation of peptides and proteins: an experimental hazard and a possible biological timer. , 1970, Proceedings of the National Academy of Sciences of the United States of America.

[88]  S. Clarke,et al.  Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. , 1987, The Journal of biological chemistry.

[89]  L. Presta,et al.  Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. , 1996, Biochemistry.

[90]  Y. Matsuoka,et al.  Biological significance of isoaspartate and its repair system. , 2005, Biological & pharmaceutical bulletin.

[91]  W. Xu,et al.  Developability studies before initiation of process development , 2013, mAbs.

[92]  Ronald T. Borchardt,et al.  Chemical Pathways of Peptide Degradation. II. Kinetics of Deamidation of an Asparaginyl Residue in a Model Hexapeptide , 1990, Pharmaceutical Research.

[93]  Ronald T Borchardt,et al.  Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. , 2007, Biochemistry.

[94]  D. Chelius,et al.  Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[95]  M. Sawai,et al.  Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon. , 2005, Journal of pharmaceutical sciences.